Browsing Pathways
Showing 64991 -
65000 of 605359 pathways
SMPDB ID | Pathway Name and Description | Pathway Class | Chemical Compounds | Proteins |
---|---|---|---|---|
SMP0145343View Pathway |
13-cis-Retinoic acid Drug Metabolism Pathway |
|
||
SMP0000575View Pathway |
11-beta-Hydroxylase Deficiency (CYP11B1)11-beta-Hydroxylase Deficiency, also called congenital adrenal hyperplasia (CAH), is an autosomal recessive disorder and caused by a defective 11-beta-hydroxylase. 11-beta-hydroxylase catalyzes the conversion of cortexolone into cortisol which is useful for maintaining blood sugar levels and suppressing inflammation. This disorder is characterized by a large accumulation of cortexolone in the endoplasmic reticulum (ER). Symptoms of the disorder include abnormality of hair growth rate and menstrual cycle. It is estimated that 11-beta-hydroxylase deficiency affects 1 in 100,000 to 200,000 newborns.
|
Disease
|
|
|
SMP0125800View Pathway |
11-beta-Hydroxylase Deficiency (CYP11B1)11-beta-Hydroxylase Deficiency, also called congenital adrenal hyperplasia (CAH), is an autosomal recessive disorder and caused by a defective 11-beta-hydroxylase. 11-beta-hydroxylase catalyzes the conversion of cortexolone into cortisol which is useful for maintaining blood sugar levels and suppressing inflammation. This disorder is characterized by a large accumulation of cortexolone in the endoplasmic reticulum (ER). Symptoms of the disorder include abnormality of hair growth rate and menstrual cycle. It is estimated that 11-beta-hydroxylase deficiency affects 1 in 100,000 to 200,000 newborns.
|
Disease
|
|
|
SMP0144686View Pathway |
1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)) Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0124716View Pathway |
1-Methylhistidine MetabolismMethylhistidine is a modified amino acid that is produced in myocytes during the methylation of actin and myosin. It is also formed from the methylation of L-histidine, which takes the methyl group from S-adenosylmethionine and forms S-adenosylhomocysteine as a byproduct. After its formation in the myocytes, methylhistidine enters the blood stream and travels to the kidneys, where it is excreted in the urine. Methylhistidine is present in the blood and urine in higher concentrations after skeletal muscle protein breakdown, which can occur due to disease or injury. Because of this, it can be used to judge how much muscle breakdown is occurring. Methylhistidine levels are also affected by diet, and may differ between vegetarian diets and those containing meats.
|
|||
SMP0127816View Pathway |
1-Azepan-1-Yl-2-Phenyl-2-(4-Thioxo-1,4-Dihydro-Pyrazolo[3,4-D]Pyrimidin-5-Yl)Ethanone Adduct Drug Metabolism |
|
||
SMP0145083View Pathway |
1,2-icosapentoyl-sn-glycero-3-phosphoserine Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0145084View Pathway |
1,2-Distearoyllecithin Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0144873View Pathway |
1,2-Benzodiazepine Drug Metabolism Action Pathway |
Drug Action
|
|
|
SMP0130706View Pathway |
1,2-Benzodiazepine Drug Metabolism1,2-Benzodiazepine is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. 1,2-Benzodiazepine passes through the liver and is then excreted from the body mainly through the kidney.
|
|
Showing 64991 -
65000 of 65006 pathways